Stock News & Analysis

Rising oil prices are pressuring the cruise operator.

This architectural glass manufacturer, serving major markets across the Americas, reported a recent insider buy in official filings.

These two coins now have fewer obstacles blocking their growth.

This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.

This annuities and life insurance provider saw a notable insider buy amid a year marked by sharp share price declines and sector headwinds.

If the defense budget tops $1 trillion, Lockheed stands to make a fortune.

Data centers devour energy. Argan builds the power plants that feed them.

LeMaitre Vascular, a specialist in vascular medical devices, reported a notable insider sale amid strong recent share gains.

This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.

Analysts think Nebius, Microsoft, and Nvidia have huge upsides.

This spine-focused medtech firm, known for its surgical innovations, reported a notable insider sale amid ongoing portfolio expansion.

As stocks sell off, here's one of the Magnificent Seven stocks I think has fallen enough to make it a buy.

It was a historic stretch of time for the biotech.

This investment offers a terrific combination of likely price appreciation along with dividend income.

This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.

This error could really trip you up.

The company crushed bottom-line estimates in its final quarter of 2025.

This clinical-stage biotech advancing neurological therapies reported a notable insider sale as it progresses its drug pipeline.

Investors are concerned about restrictive regulations against social media companies.

Could Novo Nordisk be the hidden gem you've been searching for? Join us as we evaluate its current market position and future prospects in this insightful episode.